Wall Street looks bullish on Biogen’s (BIIB) prospects after the company’s success during the Phase 3 clinical trial of lecanemab. The drug could boost the company’s financials significantly as it…
Wall Street looks bullish on Biogen’s (BIIB) prospects after the company’s success during the Phase 3 clinical trial of lecanemab. The drug could boost the company’s financials significantly as it…